Faeth Therapeutics, Inc. (FTH)
$23.25-10.68%Close
SELLCRISIS · day 19
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $31M
- Beta
- -0.28
- P/E (TTM)
- -0.19
- Short % float
- 838.84%
- Days to cover
- 3.6
- SI change
- +56.8%
- 1W
- -14.21%
- 1M
- -37.90%
- vs SPY 1W
- -14.63%
- vs SPY 1M
- -39.96%
Industry peers
FMP comparable companies · ranked by market cap
- RLAYSELLRelay Therapeutics, Inc.$3.9BRECOVERYQ 3$17.95+0.56%
- TNGXSELLTango Therapeutics, Inc.$3.6BRECOVERYQ 24$21.83+1.51%
- NUVBSELLNuvation Bio Inc.$1.7BCRISISQ 4$4.86-2.00%
- JANXBUYJanux Therapeutics, Inc.$1.1BRECOVERYQ 12$17.92-1.31%
- KURASELLKura Oncology, Inc.$947MBEARQ 12$10.67-1.89%
- VSTMBUYVerastem, Inc.$726MRECOVERYQ 4$8.27-1.55%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on FTH?
- LOPJLB’s latest quantitative signal on Faeth Therapeutics, Inc. (FTH) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is FTH in?
- Faeth Therapeutics, Inc. (FTH) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Faeth Therapeutics, Inc. (FTH) do?
- Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]